共 40 条
[1]
Yadav MP(2016)Lu-DKFZ-PSMA-617 therapy in metastatic castration resistant prostate cancer: safety, efficacy, and quality of life assessment Eur J Nucl Med Mol Imaging undefined undefined-undefined
[2]
Ballal S(2015)Early side effects and first results of radioligand therapy with (177)Lu-DKFZ-617 PSMA of castrate-resistant metastatic prostate cancer: a two-centre study EJNMMI Res undefined undefined-undefined
[3]
Tripathi M(2016)Therapeutic response and side effects of repeated radioligand therapy with Oncotarget undefined undefined-undefined
[4]
Damle NA(2016)Lu-PSMA-DKFZ-617 of castrate-resistant metastatic prostate cancer Clin Nucl Med undefined undefined-undefined
[5]
Sahoo RK(2008)Radioligand therapy with J Clin Oncol undefined undefined-undefined
[6]
Seth A(2014)Lu-PSMA-617 as a novel therapeutic option in patients with metastatic castration-resistant prostate cancer EJNMMI Res undefined undefined-undefined
[7]
Ahmadzadehfar H(2009)Prostate cancer clinical trials working group. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the prostate cancer clinical trials working group J Nucl Med undefined undefined-undefined
[8]
Rahbar K(undefined)Prediction of clinically relevant hyperkalemia in patients treated with peptide receptor radionuclide therapy undefined undefined undefined-undefined
[9]
Kurpig S(undefined)From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors undefined undefined undefined-undefined
[10]
Bogemann M(undefined)undefined undefined undefined undefined-undefined